WASHINGTON, DC, Nov. 10, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Xalles Holdings Inc. (OTC: XALL), a fintech holding company providing technology and financial services solutions, is announcing today that Argus Technology Partners, Inc. (“Argus”), a wholly owned subsidiary of Xalles Technology Inc., has executed a Master Reseller Agreement (MRA) with AMT-USC, LLC, which stands for American Made Technologies-United States Corporation (“AMT”), to provide quantum computing and biometric security solutions.
Argus plans to bring the AMT solutions to specific markets including banking and finance, healthcare, energy and government agencies. This agreement is expected to generate over $2 million in revenue to Argus within the first 12 months.
AMT-USC has been creating breakthrough solutions in advanced Multi Biometric ICAM, Quantum Application Emulation Software, Quantum Virtual Server Systems, Neural AI predictive software and High V Security Solutions, and becoming a provider of the National Defense Initiatives-2019 supplying Defense and Intel Agencies. AMT is working with DARPA, the FBI, and DISA in product development to support requests to present to DoD, Sandia Labs, DoE, QIE Quantum Alliance, NRC, NASA, NSA and other agencies.
Intelligence Analytics, Person of Interest Quantum Pattern Facial Recognition, Biometric ICAM, Military Biometric Vehicle access, Fleet Defense Naval Agencies, Battle Control Predictive Analytics and Military Simulations, and Launch Vehicle Protection are some of the specific applications that AMT solutions provide.
“The Argus team is pleased to be partnering with AMT through this Master Reseller Agreement to bring these innovative technology solutions to our vast independent sales network,” stated David Baldwin, Argus Technology Partners President. “We identified immediate project opportunities for the AMT biometric security and quantum computing solutions that will produce tremendous revenue for both companies. We also saw synergies with our other technology partners for solutions integration.”
Argus will initially be focused on deploying the Multi Biometric ICAM, Quantum Application Emulation Software, and Quantum Virtual Server Systems to its client base.
About Xalles Holdings Inc. (OTC: XALL)
Xalles Holdings Inc. is a holding company that focuses on direct investments in disruptive fintech companies. The company actively seeks acquisition targets in which it can invest and accelerate growth, targeting companies with solid management teams and business models, large total attainable markets (TAM), and lucrative exit opportunities. The company places emphasis on leveraging blockchain technologies to provide industry-leading financial reconciliation and auditing solutions, which, over time, will allow for the capture of recurring revenue streams. For more information visit: http://Xalles.com
About AMT-USC, LLC
Cutting edge software developers since 1990, creating the first Satellite Based Image Processing software (now called GIS) to one of the first RAID 5 hardware and software solutions. AMT, started in 2011, continued development of advanced hardware and advanced software solutions for security, healthcare and cloud technology, this led to the founding of AMT-USC, LLC in January 2017. In late 2019, AMT initiated product rollouts in the commercial sector. The AMT-USC solutions are now being acquired and adapted by Energy, Oil, Mining, Banking and Finance, Transportation and Logistics, Smart Car Guidance, Commercial Drone Flight Path Control and Air Traffic Control with great success. “We turn Quantum Physics into Solutions." For more information visit: http://www.amtusc.com
About Argus Technology Partners, Inc.
Argus Technology Partners is a technology solutions company, and a wholly owned subsidiary of Xalles Technology Inc. Argus’ unique advantage is their reach into a wide range of U.S. and international companies in multiple vertical markets, from financial services, healthcare and manufacturing as well as food services, technology companies and government agencies. For more information visit https://argustechpartnersinc.com/
Forward-Looking Statements Disclaimer:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," "will," "would," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov and in OTC Markets at www.otcmarkets.com
$RXMD Strong Revenues for 2020: Progressive Care Announces Nine Month Sales of $30.2 Million, Increase of 31% and Updates September Performance
MIAMI, FL, Nov. 05, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – Progressive Care Inc. (OTCQB: RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is pleased to announce preliminary topline performance data for the three- and nine-month periods ended September 30, 2020, reflecting strong overall growth in sales and prescriptions, breakout expansion in the Company’s 340B segment, and anticipated progress towards the launch of telemedicine services before year-end.
Consolidated gross sales across all locations during the nine months ended September 30, 2020, totaled $30.2 million, representing a 31% increase in total revenues compared to the nine months ended September 30, 2019. Consolidated gross sales across all locations during the three months ended September 30, 2020, totaled $10.72 million, representing a 2% increase in total revenues compared to the three months ended September 30, 2019. Fees for 340B services during the month of September 2020 jumped to $390k, an increase of 520% on a year-over-year basis. Monthly gross sales across all locations for the month of September 2020 increased 8% on a year-over-year basis Prescriptions filled during the month of September 2020 were 45,162, representing a 6% jump in total prescriptions on a year-over-year basis “In very basic terms, so far this year, we have nearly equaled our total gross sales from all of last year, and we still have a quarter to go,” commented Alan Jay Weisberg, CEO and Chairman of Progressive Care. “That’s certainly a welcome accomplishment, as we are continuing to pick up steam in our telemedicine and health data management initiatives with a nationwide target reach.”
The Company anticipates a full live launch of its enhanced telemedicine platform later this quarter, with the initial launch focused on the Florida market, and a wider nationwide launch to follow shortly thereafter.
“While this represents an extremely challenging time for our country, Progressive Care remains grateful to be making a positive contribution to the communities we serve,” added Mr. Weisberg. “We have established a leadership brand in delivering a rapid COVID-19 testing solution, providing testing results to over 1000 people just in the last 30 days. We are committed to expanding testing capabilities to all our locations as soon as the Company receives more analyzers and we are preparing our team for participation in distribution and administration of COVID-19 vaccines, once approved by FDA.”
For more information about Progressive Care, please visit the company’s website. Connect and stay in touch with us on social media:
Progressive Care Inc. (OTCQB: RXMD), through its subsidiaries, is a Florida health services organization and provider of prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.
Cautionary Statement Regarding Forward-Looking Statements Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company’s expectations about its future operating results, performance, and opportunities that involve substantial risks and uncertainties. These statements include but are not limited to statements regarding the Company’s performance data for the three and nine-month ended September 30th, 2020, as well as the projected launch of the Company’s telemedicine platform during the 4th quarter of 2020. When used herein, the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target,” “intend” and “expect” and similar expressions, as they relate to Progressive Care Inc., its subsidiaries, or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company’s actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
Public Relations Contact: Carlos Rangel carlosr@pharmcorx.com
News 
Market Data 
Discover 
